---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005549"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:56:40.531481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing

## Summary
- Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.
- Revenue $9.4M for FY2022 vs $18.4M in 2021; no Q4 revenue.
- Cash and marketable securities $720.8M as of Dec 31, 2022; sufficient into 2026.
- XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) enrolling; topline MDD data expected Q3 2023.
- Neurocrine partner Phase 2 FOS data expected H2 2023; XEN496 Phase 3 EPIK completion expected 2024.

## SEC filing metadata
- accession: 0000950170-23-005549
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/0000950170-23-005549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/xene-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005549
- JSON: https://secwatch.observer/filing/0000950170-23-005549.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005549.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 1, 2023, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/0000950170-23-005549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.